Aclarion Inc
NASDAQ:ACON

Watchlist Manager
Aclarion Inc Logo
Aclarion Inc
NASDAQ:ACON
Watchlist
Price: 6.105 USD 3.83% Market Closed
Market Cap: 4.1m USD

ACON's latest stock split occurred on Mar 28, 2025

The company executed a 1-for-27 stock split, meaning that for every 27 shares held, investors received 1 new share.

Before the split, ACON traded at 0.522 per share. Afterward, the share price was about 12.12.

The adjusted shares began trading on Mar 28, 2025. This was ACON's 3rd stock split, following the previous one in Jan 30, 2025.

Last Splits:
Mar 28, 2025
1-for-27
Jan 30, 2025
1-for-335
Jan 4, 2024
1-for-16
Pre-Split Price
14.094 0.522
Post-Split Price
12.12
Before
After
Last Splits:
Mar 28, 2025
1-for-27
Jan 30, 2025
1-for-335
Jan 4, 2024
1-for-16

Aclarion Inc
Stock Splits History

ACON Stock Splits Timeline
Mar 28, 2025
Mar 28, 2025
Split 1-for-27
/0.037037037037037
Pre-Split Price
14.094 0.522
Post-Split Price
12.12
Before
After
Jan 30, 2025
Jan 30, 2025
Split 1-for-335
/0.0029850746268657
Pre-Split Price
253.26 0.028
Post-Split Price
226.8
Before
After
Jan 4, 2024
Jan 4, 2024
Split 1-for-16
/0.0625
Pre-Split Price
30 246.4805 0.209
Post-Split Price
27 949.0508
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Dec 29, 2025
Ise Chemicals Corp
OTC:ICHMF
10-for-1
x10
32.808 32.808 USD N/A
Dec 29, 2025
Bridgestone Corp
OTC:BRDCF
2-for-1
x2
45.22 45.22 USD N/A
Dec 29, 2025
Ibiden Co Ltd
OTC:IBIDF
2-for-1
x2
81 81 USD N/A
Dec 29, 2025
Itochu Corp
OTC:ITOCF
5-for-1
x5
61.4 61.4 USD N/A
Dec 29, 2025
Sumitomo Realty & Development Co Ltd
OTC:SURDF
2-for-1
x2
47.945 47.945 USD N/A
Load More

Aclarion Inc
Glance View

Market Cap
4.1m USD
Industry
Health Care

Aclarion Inc is a US-based company operating in Health Care Technology industry. The company is headquartered in San Mateo, California. The company went IPO on 2022-04-22. Aclarion, Inc. is a healthcare technology company that employs magnetic resonance spectroscopy (MRS) and artificial intelligence (AI) technology to optimize clinical treatments. The Company’s technology is focused on improving surgical decision making when surgical intervention is being contemplated for patients with low back pain. Its first commercial product, NOCISCAN-LS, utilizes its proprietary biomarkers and algorithms to provide surgeons with information about which intervertebral discs are determined to be consistent with generating pain, and which are not. NOCISCAN is a software as a service (SaaS) platform to leverage MRS to non-invasively help physicians distinguish between painful and nonpainful discs in the spine. The platform used to conduct a NOCISCAN-LS involves NOCISCAN-LS MRS exam protocol, data transfer, and the NOCISCAN-LS post-processor suite. The Company’s NOCISCAN-LS post processor suite is comprised of two software products, such as NOCICALC-LS and NOCIGRAM.

ACON Intrinsic Value
Not Available
Back to Top